BRPI0409604A - medicamento para a terapia perioperatória em duas etapas de tumores sólidos - Google Patents

medicamento para a terapia perioperatória em duas etapas de tumores sólidos

Info

Publication number
BRPI0409604A
BRPI0409604A BRPI0409604-5A BRPI0409604A BRPI0409604A BR PI0409604 A BRPI0409604 A BR PI0409604A BR PI0409604 A BRPI0409604 A BR PI0409604A BR PI0409604 A BRPI0409604 A BR PI0409604A
Authority
BR
Brazil
Prior art keywords
solid tumors
drug
stages
therapy
reduction
Prior art date
Application number
BRPI0409604-5A
Other languages
English (en)
Inventor
Giovanni Paganelli
Paolo Carminati
Umberto Veronesi
Original Assignee
Sigma Tau Ind Famaceutiche Riu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Famaceutiche Riu filed Critical Sigma Tau Ind Famaceutiche Riu
Publication of BRPI0409604A publication Critical patent/BRPI0409604A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

"MEDICAMENTO PARA A TERAPIA PERIOPERATóRIA EM DUAS ETAPAS DE TUMORES SóLIDOS". A presente invenção refere-se ao uso de um agente dotado de tropismo do tumor em combinação com um outro agente com atividade anticâncer e com uma afinidade pelo primeiro agente para a preparação de um medicamento útil para a terapia perioperatória em duas etapas de tumores sólidos. As vantagens da presente invenção consistem em uma maior, eficaz localização de sua atividade anticâncer, na redução do número de etapas de administração e na possibilidade de redução das doses anticâncer, com uma diminuição resultante de efeitos colaterais, porém sem perda alguma de eficiência.
BRPI0409604-5A 2003-04-24 2004-04-07 medicamento para a terapia perioperatória em duas etapas de tumores sólidos BRPI0409604A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000196A ITRM20030196A1 (it) 2003-04-24 2003-04-24 Uso di reagenti per la preparazione di un medicamento
PCT/IT2004/000184 WO2004093916A1 (en) 2003-04-24 2004-04-07 A medicament for the two-step perioperative therapy of solid tumours

Publications (1)

Publication Number Publication Date
BRPI0409604A true BRPI0409604A (pt) 2006-04-18

Family

ID=29765781

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409604-5A BRPI0409604A (pt) 2003-04-24 2004-04-07 medicamento para a terapia perioperatória em duas etapas de tumores sólidos

Country Status (20)

Country Link
US (1) US7935346B2 (pt)
EP (1) EP1615668B1 (pt)
JP (1) JP4949016B2 (pt)
KR (1) KR20060005383A (pt)
CN (1) CN1777446A (pt)
AR (1) AR044052A1 (pt)
AU (1) AU2004231377B2 (pt)
BR (1) BRPI0409604A (pt)
CA (1) CA2522580C (pt)
CY (1) CY1113488T1 (pt)
DK (1) DK1615668T3 (pt)
ES (1) ES2398389T3 (pt)
HR (1) HRP20121052T8 (pt)
IT (1) ITRM20030196A1 (pt)
MX (1) MXPA05011293A (pt)
PL (1) PL1615668T3 (pt)
PT (1) PT1615668E (pt)
SI (1) SI1615668T1 (pt)
TW (1) TWI368518B (pt)
WO (1) WO2004093916A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
BRPI0815050B8 (pt) * 2007-08-02 2021-05-25 Alfasigma Spa avidina oxidada com tempo de permanência elevado em tecidos tratados, complexo compreendendo a referida avidina e uso dos mesmos, composição farmacêutica, kit, bem como processo de oxidação de avidina
IT1398977B1 (it) 2009-06-25 2013-03-28 Icgeb Agente anticancro specifico per i tumori cerebrali con meccanismo di soppressione di recq1
CN103717239B (zh) * 2011-08-02 2017-08-01 希格马托制药工业公司 适合于吸入的氧化抗生物素蛋白的药物组合物
US20160331853A1 (en) * 2014-01-21 2016-11-17 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
DE69433343D1 (de) 1993-12-07 2003-12-24 Neorx Corp Pretargeting verfahren und mitteln
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
CA2449941A1 (en) 2001-06-11 2002-12-19 University Of Miami Use of radiopharmaceutical complexes in achieving transplantation tolerance
ITRM20020071A1 (it) 2002-02-11 2003-08-11 Sigma Tau Ind Farmaceuti Contenitore per flacone di radiofarmaco, e corredo per la sua infusione in un paziente o per il suo trasferimento altrove.
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento

Also Published As

Publication number Publication date
EP1615668A1 (en) 2006-01-18
US20060251579A1 (en) 2006-11-09
JP4949016B2 (ja) 2012-06-06
HRP20121052T1 (hr) 2013-01-31
CA2522580A1 (en) 2004-11-04
AU2004231377A1 (en) 2004-11-04
AR044052A1 (es) 2005-08-24
PL1615668T3 (pl) 2013-03-29
ITRM20030196A0 (it) 2003-04-24
MXPA05011293A (es) 2006-01-24
HRP20121052T8 (en) 2013-03-31
CN1777446A (zh) 2006-05-24
ES2398389T3 (es) 2013-03-15
WO2004093916A8 (en) 2005-11-03
SI1615668T1 (sl) 2013-01-31
TW200501984A (en) 2005-01-16
ITRM20030196A1 (it) 2004-10-25
WO2004093916A1 (en) 2004-11-04
PT1615668E (pt) 2013-01-14
CY1113488T1 (el) 2016-06-22
TWI368518B (en) 2012-07-21
EP1615668B1 (en) 2012-12-05
AU2004231377B2 (en) 2010-08-05
KR20060005383A (ko) 2006-01-17
JP2006524235A (ja) 2006-10-26
US7935346B2 (en) 2011-05-03
DK1615668T3 (da) 2013-02-04
CA2522580C (en) 2013-08-06

Similar Documents

Publication Publication Date Title
WO2002028832A3 (en) Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BRPI0407648A (pt) uso de uma proteìna ligante sìtio-especìfica ativa juntamente com um vetor terapêutico codificando uma proteìna para manufatura de um medicamente
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BRPI0608297A2 (pt) composições de lipossomos
WO2002049501A3 (en) Local regional chemotherapy and radiotherapy using in situ hydrogel
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
WO2006083779A3 (en) Pharmaceutical composition comprising hydroxylated nebivolol
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
BR0115162A (pt) Tratamentos antitumorais eficazes
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
PT1037648E (pt) Utilizacao de preparados de eritropoietina e ferro para a producao de preparados de combinacao farmaceutica para o tratamento de doencas reumaticas
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
DE69817602D1 (de) Arzneistoffverabreichungssystem mit zweistufigem targeting
TR200201089T2 (tr) Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
BRPI0409604A (pt) medicamento para a terapia perioperatória em duas etapas de tumores sólidos
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
PL368686A1 (en) Novel aminobenzoephenones
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4188 (2006.01), A61K 39/395 (2006.01), A61

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 31/4188 (2006.01), A61K

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]